Palatin Technologies, Inc. (PTNT)

Market Cap	6.69M
Revenue (ttm)	350.00K
Net Income (ttm)	-23.33M
Shares Out	n/a
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,290
Average Volume	203,118
Open	0.1402
Previous Close	0.1402
Day's Range	0.1375 - 0.1445
52-Week Range	0.0350 - 0.1663
Beta	n/a
RSI	55.44
Earnings Date	Sep 30, 2025

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide m...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 30
• Stock Exchange: OTCMKTS
• Ticker Symbol: PTNT

Financial Performance

In 2024, Palatin Technologies's revenue was $4.49 million, a decrease of -7.49% compared to the previous year's $4.85 million. Losses were -$29.74 million, 23.7% more than in 2023.